Nuvisan receives US$25 million grant from the Gates Foundation to help bring novel non-hormonal contraceptives to life.
Read more
See the latest testimonials about how partnering with Nuvisan has helped clients achieve their goals.
Read now
Our analytical services for small and large molecules include method development, validation, quality control, stability studies, EU re-testing and commercial release.
Contact us
Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration.
Learn More
Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic.
Learn More
Empowering your drug discovery and development with integrated data services, machine learning and generative AI.
Learn MoreSupporting you with integrated, tailored solutions at every step of your drug discovery and development journey.
Nuvisan is the unique CRO/CDMO with extensive pharma experience and industry-leading scientific expertise, providing highest-quality end-to-end solutions. From enabling target understanding to helping get innovative medicines to the patients who need them, we provide support that streamlines and accelerates drug discovery and development.
Explore or search our library of brochures to find out how our solutions drive drug discovery and development.
Learn More
Read what our clients are saying about how partnering with Nuvisan supports them on their scientific journey.
Learn More.jpg)
Experience engaging, in-depth looks at how our services, solutions and expertise advance projects to enable breakthrough therapies.
Learn More
June 11, 2026
The new three-year grant from the Gates Foundation builds on a successful program, delivered over the past three years. It is intended to further expand the pipeline of non-hormonal contraceptive candidates, an area of significant unmet need in global health.
Learn more
Contact Us
Search
